**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 43221

**Manuscript Type:** ORIGINAL ARTICLE

***Prospective Study***

**Split-dose or hybrid nonsteroidal anti-inflammatory drugs and N-acetylcysteine therapy for prevention of post- retrograde cholangiopancreatography** **pancreatitis**

Pavel L *et al*. Pharmacological prophylaxis of post-ERCP pancreatitis

**Laura Pavel, Gheorghe Gh Bălan, Alexandra Nicorescu, Georgiana Emmanuela Gîlcă-Blănariu, Cătălin Sfarti, Ștefan Chiriac, Smaranda Diaconescu, Vasile Liviu Drug, Gheorghe Bălan, Gabriela Ștefănescu**

**Laura Pavel, Gheorghe Gh Bălan, Georgiana Emmanuela Gîlcă-Blănariu, Cătălin Sfarti, Ștefan Chiriac, Vasile Liviu Drug, Gheorghe Bălan, Gabriela Ștefănescu,** Gastroenterology,“Grigore T. Popa” University of Medicine and Pharmacy, Iași 700115, România

**Alexandra Nicorescu,** Endocrinology,“Grigore T. Popa” University of Medicine and Pharmacy, Iași 700115, România

**Smaranda Diaconescu,** Department of Mother and Child Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iași 700115, România

**ORCID number:** Laura Pavel ([0000-0003-2194-4345](https://orcid.org/0000-0003-2194-4345)); Gheorghe Gh Bălan ([0000-0001-9789-8280](https://orcid.org/0000-0001-9789-8280)); Alexandra Nicorescu ([0000-0002-1090-9520](https://orcid.org/0000-0002-1090-9520%22%20%5Ct%20%22_blank)); Georgiana Emmanuela Gîlcă-Blănariu ([0000-0002-5590-6462](https://orcid.org/0000-0002-5590-6462)); Cătălin Sfarti ([0000-0001-7074-5938](https://orcid.org/0000-0001-7074-5938)); Ștefan Chiriac ([0000-0003-2497-9236](https://orcid.org/0000-0003-2497-9236)); Smaranda [Diaconescu (0000-0001-8018-7191](https://orcid.org/0000-0001-8018-7191)); Vasile Liviu Drug ([0000-0002-7596-2656](https://orcid.org/0000-0002-7596-2656)); Gheorghe Bălan ([0000-0002-2919-4940](https://orcid.org/0000-0002-2919-4940)); Gabriela Ștefănescu ([0000-0002-1394-8648](https://orcid.org/0000-0002-1394-8648)).

**Author contributions:** Pavel L, Bălan GG, Blănariu-Gîlcă EG, Bălan G and Ștefănescu G, participated in the protocol design, identification and inclusion of candidates, collection of clinical information, and patient follow-up; Bălan GG, Sfarti C, Drug VL, Chiriac S band Bălan G performed the endoscopic interventions; Pavel L, Diaconescu S, Nicorescu A and Ștefănescu G participated in the protocol design and statistical analysis; all authors were involved in critical review of the results and approved the final manuscript.

**Institutional review board statement:** The Institutional Review Board of “Gr. T. Popa” University of Medicine and Pharmacy - Iași provided approval for this study (IRB No. 27/03/2017).

**Clinical trial registration statement:** This study is registered at ClinicalTrials.gov, registration number NCT03708458.

**Informed consent statement:** Consent was obtained from all the patients that were included in the study.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**CONSORT 2010 statement:** The CONSORT 2010 Statement was uploaded.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author to: Smaranda Diaconescu, MD, PhD, Associate Professor,** Department of Mother and Child Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universității str, Iași 700115, România. turti23@yahoo.com

**Telephone:** +40-74492216

**Fax:** +40-232222453

**Received:** October 30, 2018

**Peer-review started:** October 31, 2018

**First decision:** November 15, 2018

**Revised:** December 18, 2018

**Accepted:** December 21, 2018

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Despite significant technical and training improvements, the incidence of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) has not significantly dropped. Although many studies have evaluated the efficacy of various agents, *e.g.* nonsteroidal anti-inflammatory drugs, octreotide, antioxidants, administered *via* various dosages, routes (oral, intrarectal or parenteral), and schedules (before or after the procedure), the results have been conflicting.

***AIM***

To evaluate efficacy of three pharmacologic prophylactic methods for prevention of PEP.

***METHODS***

In this prospective, single-center randomized trial, patients who underwent first-time ERCP for choledocholithiasis were randomly assigned to three groups. The first group received 600 mg N-acetylcysteine 15 min prior to ERCP, and per-rectum administration of 50 mg indomethacin both prior to and after completion of the ERCP. The second group was administered only the 50 mg indomethacin per-rectum both prior to and after the ERCP. The third group was administered per-rectum 100 mg indomethacin only after the ERCP, representing the control group given the guideline-recommended regimen. The primary end-point was PEP prevention.

***RESULTS***

Among the total 211 patients evaluated during the study, 186 fulfilled the inclusion criteria and completed the protocol. The percentages of patients who developed PEP in each of the three groups were not significantly different (*2* = 2.793, *P* = 0.247). Among the acute PEP cases, for all groups, 14 patients developed mild pancreatitis (77.77%) and 4 moderate. No severe cases of PEP occurred, and in all PEP cases the resolution was favorable. No adverse events related to the medications (digestive hemorrhage, rectal irritation, or allergies) occurred.

***CONCLUSIONS***

The efficacies of split-dose indomethacin and combined administration (N-acetylcysteine with indomethacin) for preventing PEP were similar to that of the standard regimen.

**Key words:**Endoscopic retrograde cholangiopancreatography; Prophylaxis; Post-ERCP pancreatitis; Nonsteroidal anti-inflammatory drugs; N-acetylcysteine

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Despite significant technical and training improvements, the incidence of post-endoscopic retrograde-cholangiopancreatography (ERCP) pancreatitis has not dropped significantly. The present prospective, single-center randomized trial aimed to evaluate the efficacy of three prophylactic approaches for preventing post-ERCP pancreatitis. The results obtained demonstrate that the efficacies for preventing post-ERCP pancreatitis for both split-dose administration of indomethacin and combined administration of N-acetylcysteine before the procedure with administration of indomethacin post-ERCP are similar to that of the guideline-recommended regimen; although, a slightly more rapid improvement in the biological response was observed for the study group receiving the combination therapy (nonsteroidal anti-inflammatory drugs associated with N-acetylcysteine).

Pavel L, Bălan GG, Nicorescu A, Gîlcă-Blănariu GE, Sfarti C, Chiriac S, Diaconescu S, Drug VL, Bălan G, Ștefănescu G. Split-dose or hybrid NSAIDs and N-acetylcysteine therapy for prevention of post-ERCP pancreatitis. *World J Clin Cases* 2018; In press

**INTRODUCTION**

Endoscopic retrograde cholangiopancreatography (ERCP) is a complex endoscopic technique. Although ERCP should be a safe procedure for the vast majority of patients, postprocedural complications may arise, among which acute pancreatitis is the most frequently reported. The mean estimated incidence of this complication is 4%-5.5%, representing a wide range of rates reported in the various studies⎯from as low as 0.4% up to 40%, depending on the presence of various risk factors[1-3].

Despite continuous improvements in the equipment used and the increased training of endoscopy teams, the incidence of this complication has not dropped significantly[2,4-6]. The relatively high incidence and mortality rates (with the latter reaching approximately 0.5%) underlie the substantial research interest in studying the related pathophysiology, risk factors and potential prophylactic measures. This is also reflected by the numerous studies focusing on such objectives that have appeared throughout the literature within the last two decades alone[5-8].

Regarding the risk factors for post-ERCP pancreatitis (PEP), most studies have reported young age, normal serum bilirubin level, personal history of acute PEP, female sex, difficult cannulation of the papilla, injection of contrast agent in the pancreatic duct, and excessive use of the guidewire[1,2,4-6,9-13]. Studies on the prophylaxis of acute PEP have identified pancreatic stent placement as having the highest efficiency in preventing this event in high-risk patients, and consequently this method has been recommended by some guidelines[11-13]. All things considered, pancreatic duct stenting is a difficult, costly maneuver and is not routinely indicated for all patients undergoing ERCP[11].

Although many studies have evaluated the efficacy of various agents [nonsteroidal anti-inflammatory drugs (NSAIDs), octreotide, antioxidants] administered *via* various dosages, routes (oral, intrarectal or parenteral), and schedules (before or after the procedure)[14-25], the results have been conflicting. Thus, we established a single-blind prospective randomized trial with the aim of evaluating the efficacy of three pharmacologic prophylactic approaches in the prevention of PEP.

**MATERIAL AND METHODS**

***Patients***

The study was performed in a tertiary care center – the Institute of Gastroenterology and Hepatology of the St. Spiridon County Clinical Emergency Hospital in Iași, Romania–between April 2017 and July 2018. The study design was that of a prospective, single-blind randomized trial for comparing and dynamically evaluating the efficacy of three pharmacological combination therapies (indomethacin in various doses with or without an extra dose of N-acetylcysteine (NAC) for prevention of acute pancreatitis in patients with choledocholithiasis and indication for undergoing ERCP.

All patients were evaluated before inclusion in the study. Inclusion criteria consisted of positive diagnosis of choledocholithiasis by magnetic resonance cholangiopancreatography (commonly known as MRCP), age above 18-years-old, willingness to participate in the study, and legal capacity to sign the informed consent form. Exclusion criteria were: Presence of acute or chronic ongoing pancreatitis or other inflammatory diseases at admission; positive history for acute or chronic pancreatitis; jaundice or recurrent upper right quadrant pain; current pregnancy; contraindication for NSAID administration; recent episode of upper digestive bleeding (less than 1 mo); hypersensibility to antioxidants; intraprocedural necessity of a prophylactic pancreatic stent insertion; or inability to perform a proper prospective follow-up.

After initial evaluation, 186 patients who fulfilled the inclusion criteria and agreed to sign the informed consent form were enrolled in the study. These study participants were randomly assigned into one of three groups. The control group (*n* = 98) underwent prophylaxis according to the European Guideline, consisting of intrarectal administration of 100 mg indomethacin after the ERCP. The study group A (*n* = 32) was administered 600 mg of NAC intravenously 15 min before the ERCP, as well as an intrarectal administration of 50 mg indomethacin both before and after the ERCP. The study group B (*n* = 56) received 50 mg of indomethacin per-rectum both before and after the ERCP.

***Study protocol***

After providing written informed consent, each study participant was evaluated to identify their precise indication for ERCP. The evaluation included disease history-taking, clinical examination, and biochemical investigations (*i.e*., complete blood count, serum and urinary pancreatic enzymes, inflammatory parameters, cholestasis and cytolisis syndrome, renal function evaluation). The positive diagnosis of choledocholithiasis was obtained for all patients through MRCP.

ERCP was performed following the standard protocol, after anesthesiology evaluation and assent, with topical pharyngeal anesthesia consisting of 2% lidocaine and intravenous administration of midazolam, ketamine and propofol. The equipment and materials used for the ERCP included a TJF series 160 duodenoscope (Olympus, Tokyo, Japan), standard sphincterotomes by Olympus and Boston Scientific (Marlborough, MA, United States), Visiglide hydrophilic guidewires by Olympus, extraction balloon catheters by Boston Scientific and Wilson-Cook Medical Inc (Bloomington, IN, United States), and/or Dormia basket extractors by Olympus. Hidrosoluble iopamidol was used as the contrast agent. No pancreatic stents were used with prophylactic intent, per study protocol, as insertion of pancreatic stents was an exclusion criteria-based potential for study bias.

All patients were continuously monitored during the procedure by an anesthetist, and the procedure-related parameters (*i.e*.,number of cannulation attempts, time for cannulation, amount of contrast agent used, duration of procedure, number of involuntary pancreatic guidewire passages) were registered in the database. Moreover, hospitalization time and all procedure- or medication-related adverse events were recorded. No patient received aggressive intravenous hydration. All patients were administered standard local hydration protocol, consisting of 1.5 mL/kg/h of lactated Ringer’s solution during the ERCP and for 8 h after. Several clinical parameters (*i.e*., abdominal pain, nausea, emesis, fever, change of bowel habit) and biological parameters (*i.e*., complete blood count, C-reactive protein (CRP), serum amylase, lipase) were recorded at both 6 h and 24 h following the ERCP procedure.

Diagnosis of PEP was established according to the criteria described by Cotton *et al*[26], namely by patient report of new-onset abdominal pain after the ERCP or worsening of pre-existent abdominal pain, and at least 3-fold increase of either serum lipase or amylase levels above the upper limit of normal (ULN). The normal ranges of serum lipase and amylase reported by the local laboratory for adults were levels below 60 U/L and 100 U/L respectively. An asymptomatic increase of either serum lipase or amylase above the ULN was not interpreted as PEP.

Patients were withdrawn from the study protocol monitoring at 24 h after undergoing the ERCP if no significant events were reported. For patients who experienced adverse events, withdrawal occurred after resolution and the patients were re-evaluated at 30 d after discharge. The data collected in all monitoring stages were recorded in an electronic database, being presented as raw values, percentages, and mean ± standard deviation. For intergroup comparisons, the Student’s *t*-test was used for continuous data and the chi-squared (χ2) or Fisher’s exact tests were used for qualitative variables when appropriate. Results were considered significant when the *P* value was < 0.05. All statistical analyses were conducted using SPSS software (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.).

The study protocol and the patient consent form were approved by the Ethics Committee of Grigore T. Popa University of Medicine and Pharmacy and St Spiridon Clinical Emergency Hospital, Iasi, Romania.

**RESULTS**

***Study groups description***

A total of 211 patients were evaluated for study participation, of which 186 fulfilled the inclusion criteria, represented by 102 women (54.8%) and 84 males (45.2%). The patients were randomized to one of the three groups as described above. The median age of all included patients was 64.32 ± 14.91 yr, without statistically significant differences between the three groups: Control group: 64.47 ± 15.403 yr *vs* Study group A: 63.56 ± 14.099 yr *vs* Study group B: 64.50 ± 15.684 yr (ANOVA test, *F* = 0.025, *P* = 0.97). Also, there was a similar number of male and female patients in the three groups (*t*-test, *t* = 1.056, *P* = 0.294, non-significant). The structure of each group with consideration to demographic, clinical and laboratory values at baseline is shown in Table 1.

Evaluation of the known risk factors involved in PEP (sex, age, bilirubin, amount of contrast medium/agent used, number of cannulations and history of acute PEP) showed no statistically significant differences between the three groups for any of the factors (Table 2). Multifactor comparative analysis of the demographic and risk factors for acute pancreatitis showed no statistically significant differences between the three groups of patients regarding the factors that might influence the features studied below (*i.e*., PEP occurrence, specific laboratory results, or responsiveness to treatment). Thus, the selected study groups are similar and represent an appropriate foundation of data for minimally-biased evaluation, promoting our ability to investigate valid comparisons between the study arms.

***Comparative analysis of the evolution of clinical features and laboratory results at 6 h and 24 h post-ERCP in the three study groups***

Efficacy of the three studied regimens was evaluated by comparing the clinical evolution and the laboratory results for the three study groups. PEP was diagnosed based on findings from clinical exam and laboratory tests (*i.e.*, pancreatic enzymes and inflammatory syndrome markers, such as white blood cell count and CRP, measured at 6 h and 24 h post-ERCP. For the evaluation of statistical significance, the Pearson's chi-squared testwas used.

Of the total 186 patients included in our study, 18 developed clinically significant acute pancreatitis after the ERCP procedure. The percentages among the three study groups were similar, with 8 patients from the control group (8.16%), 4 from Study group A (12.5%) and 6 from Study group B (10.71%) affected; the differences showed no statistical significance (*2* = 2.793, *P* = 0.247). Of note, in the majority of cases (*n* = 16) the debut was precocious, under 6 h post-ERCP, and only in 2 cases was the debut late (both those cases belonged to Study group B) (Figure 1, Tables 3 and 4). Among the acute PEP cases, 14 were mild (77.77%) and 4 were moderate. No severe cases occurred, and in all cases the outcome was favorable. No adverse events related to the study medications, including digestive hemorrhage, rectal irritation and allergies, occurred.

Resultf the comparative analysis of pancreatic enzymes and CRP at the two time points considered (6 h and 24 h post-ERCP) are summarized in Tables 3 and 4. In the Control group, 18.4% of the patients showed 3-fold ULN increase for amylasemia at 6 h post-ERCP, but only 8.2% of patients exhibited values that might be recorded as asymptomatic elevated enzyme levels, which are non-consistent with PEP, at 24 h post-ERCP. In Study group A, 25% of patients exhibited raised enzyme levels at 6 h post-ERCP and 12.5% of patients had amylase levels over the normal limit at 24 h post-ERCP; yet, none of these cases represented increases of more than 3-fold. In Study group B, 14.3% of patients exhibited asymptomatic elevated amylase levels at 6 h post-ERCP, which was similar to the percentages in the Control group and Study group A (*P* = 0.368), but the 28.6% of patients with this feature at 24 h post-ERCP represented a significantly larger pool compared to the other study arms (*P* = 0.019). This particularly worse evolution for the Study group A regimen at 24 h post-ERCP is an intriguing finding and unexplained in the scope of this study.

Lipase levels showed a similar evolution as amylasemia, with significant improvement in the Control group and Study group A (Tables 3 and 4). In the Control group, 30.6% of patients showed a 3-fold ULN increase at 6 h post-ERCP, but only 8.2% showed the same at 24 h post-ERCP. In Study group A, 31.3% of patients showed a 3-fold ULN increase at 6 hr post-ERCP, dropping to 12.5% at 24 h post-ERCP. In Study group B, the percentage of patients with a 3-fold ULN increase in lipase levels remained unchanged at both time points (being 28.6% at 6 h and 24 h), with a statistically significant difference compared to the other two study arms (6 h: *P* = 0.040 and 24 h: *P* = 0.029).

Inflammatory status, evaluated by CRP values, varied remarkably during the study time course, but significant differences between the study arms occurred only at the 24 h post-ERCP time point (*P* = 0.046) (Figure 2, Table 3 and 4).

**DISCUSSIONS**

Our study has clearly shown that there are no significant differences for PEP rates among patients treated with the standard NSAID prophylaxis, double NAC and NSAID prophylaxis, or split-NSAID regimens. Nevertheless, increased levels of PEP in both secondary or tertiary centers all around the world justify a continuous search for better prophylaxis protocols.

Acute pancreatitis remains the most frequent complication of ERCP and represents a significant cause of morbidity and mortality[3,12,26,27]. The reported incidence of this complication has varied in different studies, according to the included patients’ risk level (*i.e*., mild or medium). A recent meta-analysis of 108 controlled randomized studies, including 13296 patients, found a global incidence of 9.7%, with a median incidence of 14.7% for the high-risk patients[28]. In the present study, the acute PEP incidence was 9.67% for our overall patient population; considering there was no inclusion selection factor related to risk level, the global incidence we found was similar to that of the previously reported data[3,12].

A decrease in occurrence of acute PEP can be achieved by a thorough patient selection process, either by basing the choice of this procedure according to therapeutic use or by using special ERCP techniques[29,30]. There are several controlled studies and a meta-analysis that have demonstrated that use of prophylactic guidewire cannulation or prophylactic pancreatic duct stent might improve the incidence and seriousness of PEP, especially for high-risk patients[31-33].

From the perspective of the involved pathophysiology of PEP, many studies have evaluated the efficacy of various agents (*i.e*., NSAIDs, octreotide, antioxidants), in various dosages, with oral, intrarectal or parenteral administration routes, given before or after the procedure[14-20]. These studies have yielded conflicting results. Although many have demonstrated that intrarectal administration of NSAIDs before or after ERCP is efficient in preventing PEP⎯and as a consequence many of the international guidelines do recommend NSAIDs as a primary prophylaxis measure⎯a series of more recent studies has generally contradicted those previous findings[19-22]. Moreover, although the role of oxidative stress in the pathophysiology of this process has been clearly stated, the efficacy of various antioxidant agents in preventing PEP has not been confirmed as of yet[23-25].

On the other hand, as previously mentioned, there has been some pharmacological research for PEP prophylaxis. Most of the studied molecules specifically interfere with different steps of the inflammatory cascade. The most convincing results appear to be those related to intrarectal administered NSAIDs[16,34-36]. The efficacy has been studied according to NSAID type (indomethacin or diclofenac), dose (50 mg indomethacin *vs* 100 mg indomethacin), route of administration (intrarectal, oral, or intravenous), time of administration (before or after the ERCP), and in comparison to placebo. Several meta-analyses have shown a risk reduction related to moderate or severe PEP occurrence and a similar efficiency of the rectal administration route, immediately before or after ERCP[3,35,37].

The most cited study belongs to Elmunzer *et al*[36] and it reported the efficacy of 100 mg indomethacin suppository administered intrarectal immediately after ERCP. Although most studies have reported favorable results, a recent prospective, double-blind, placebo-controlled study showed no benefit in indomethacin administration for PEP prophylaxis or as it being protective against PEP in high-risk patients as well as in average-risk patients[22,38]. Another recent study published by Yang *et al*[29] showed efficiency of NSAIDs prophylaxis for acute PEP but reported its relation to the moment of administration, either before or after the procedure. On the other hand, some recently published papers have suggested the efficient use of other drug classes (*e.g*., nitroglycerin, antioxidants, somatostatin, antibiotics) that might be useful in PEP prophylaxis[23,39-42].

Considering the hypothesis these studies suggest, our study evaluated the efficacy of two regimens with indomethacin: One with administration of indomethacin suppository, before and after ERCP, and the other with administration of NAC (antioxidant) associated with indomethacin before and after. Our study design included both of these being compared to the standard regimen recommended by the European guidelines (*i.e*., indomethacin suppository immediately after ERCP). Upon analyzing the efficacy of these regimens for potential correlation with the incidence and seriousness of PEP we found no superiority of any regimen used (indomethacin suppository administered before and after ERCP, and indomethacin associated with NAC) compared to the regimen using indomethacin monotherapy after ERCP (*2* = 2.793, *P* = 0.247). In addition, our analysis of the serum pancreatic enzymes (amylase and lipase levels) showed that the mixed regimen had superior efficacy. Finally, the criteria for evaluating inflammatory syndrome revealed a similar evolution as the pancreatic enzymes, showing a significant improvement. Similar results have been reported in recent studies or meta-analysis[23,24].

Considering the absence of any significant difference in the prevention of PEP through different pharmacologic regimens alongside the relatively low morbidity and mortality associated with PEP in our patient groups, the main strength of our study resides in its prospective character, especially considering the current paucity of prospective trials in ERCP. Moreover, our results suggest that various pharmacologic pathogenic preventive regimens locally available may be used for PEP prophylaxis, with similar efficacy and safety profiles. Nevertheless, the main limitation of this study is that, despite the availability of at least two alternative pharmacologic preventive measures (either intravenous NSAIDs or aggressive intravenous hydration), no such alternative regimens were tested. Furthermore, in this respect, a double-blind prospective randomized controlled trial would offer stronger evidence.

The particularity of our study is that it evaluated two pharmacological therapeutic approaches (one using both NSAIDs and NAC, and the other including the usual dose but with split administration of NSAIDs) and compared these regimens with the standard therapy (recommended by the European guidelines) and not to placebo. The results obtained demonstrate that both split-dose administration of indomethacin (50 mg pre- and post-ERCP) and combined administration of 600 mg NAC before the procedure with per-rectum administration of 100 mg indomethacin post-ERCP have similar efficacy in preventing PEP, as compared to the standard guideline-recommended regimen (per-rectum administration of 100 mg indomethacin post-ERCP). However, our study also shows that the post-ERCP biological response, reflected by the number of patients developing asymptomatic hyperamylasemia and pronounced inflammatory syndrome, was attenuated in the study group receiving the combination therapy (NSAIDs associated with NAC), with a faster improvement of the biological response.

Considering these findings, further research in the field⎯eventually, through multicentric studies, enrolling high numbers of patients and modulating the antioxidant dose⎯could lead to development of a more efficient prophylactic pharmacological approach, with a satisfactory safety profile and tenable costs.

**ARTICLE HIGHLIGHTS**

***Research background***

Endoscopic retrograde cholangiopancreatography (ERCP) represents a complex endoscopic technique, which is almost exclusively used nowdays for therapeutic intent. Although ERCP should be a safe procedure for the vast majority of patients, postprocedural complications may arise, among which post-ERCP pancreatitis (PEP) is the most frequently reported.

***Research motivation***

PEP still remains an important concern with respect to its prophylaxis and management, especially considering the paucity of prospective trials in ERCP regarding this complication.

***Research objectives***

This study aimed to evaluate the efficacy of three prophylactic approaches for preventing PEP, using pharmacologic agents with different mechanisms of action (indomethacin in various doses with or without an extra dose of N-acetylcysteine (NAC) for prevention of acute pancreatitis in patients with choledocholithiasis and indication for undergoing ERCP.

***Research methods***

The study design was that of a prospective, single-blind randomized trial for comparing and dynamically evaluating the efficacy of the three pharmacological combination therapies.

***Research results***

Both split-dose administration of indomethacin (50 mg pre- and post-ERCP) and combined administration of 600 mg NAC before the procedure with per-rectum administration of 100 mg indomethacin post-ERCP showed similar efficacy in preventing PEP, as compared to the standard, guideline-reccommended regimen (per-rectum administration of 100 mg indomethacin post-ERCP).

***Research conclusions***

The results of this prospective randomized control trial support the potential use of various pharmacologic pathogenic regimens for the prophylaxis of PEP, showing similar efficacy and safety profiles. However, considering other potential prophylactic approaches, using either intravenous nonsteroidal anti-inflammatory drugs or aggressive intravenous hydration, double-blind prospective randomized controlled trials would offer stronger evidence for establishing prophylactic strategies in PEP.

***Research perspectives***

Considering these findings, further research in the field (eventually, through multicentric studies, enrolling high number of patients and modulating the antioxidant dose) could lead to developing more a efficient prophylactic pharmacological approach, with a satisfactory safety profile and tenable costs.

**ABBREVIATIONS**

ERCP: Endoscopic retrograde cholangiopancreatography

PEP: Post-ERCP pancreatitis

NSAIDs: Nonsteroidal anti-inflammatory drugs

NAC: N-acetylcysteine

**REFERENCES**

1 **Jamry A**. Risk factors of pancreatitis after endoscopic sphincterotomy. Review of literature and practical remarks based on approximately 10,000 ERCPs. *Pol Przegl Chir* 2017; **89**: 29-33 [PMID: 29154236 DOI: 10.5604/01.3001.0010.5409]

2 **Masci E**, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, Minoli G, Crosta C, Comin U, Fertitta A, Prada A, Passoni GR, Testoni PA. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *Am J Gastroenterol* 2001; **96**: 417-423 [PMID: 11232684 DOI: 10.1111/j.1572-0241.2001.03594.x]

3 **Rustagi T**, Jamidar PA. Endoscopic retrograde cholangiopancreatography-related adverse events: general overview. *Gastrointest Endosc Clin N Am* 2015; **25**: 97-106 [PMID: 25442961 DOI: 10.1016/j.giec.2014.09.005]

4 **Cheng CL**, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Lazzell-Pannell L, Rashdan A, Temkit M, Lehman GA. Risk factors for post-ERCP pancreatitis: A prospective multicenter study. *Am J Gastroenterol* 2006; **101**: 139-147 [PMID: 16405547 DOI: 10.1111/j.1572-0241.2006.00380.x]

5 **Cotton PB**, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: A multivariate analysis of 11,497 procedures over 12 years. *Gastrointest Endosc* 2009; **70**: 80-88 [PMID: 19286178 DOI: 10.1016/j.gie.2008.10.039]

6 **Ding X**, Zhang F, Wang Y. Risk factors for post-ERCP pancreatitis: A systematic review and meta-analysis. *Surgeon* 2015; **13**: 218-229 [PMID: 25547802 DOI: 10.1016/j.surge.2014.11.005]

7 **Wang P**, Li ZS, Liu F, Ren X, Lu NH, Fan ZN, Huang Q, Zhang X, He LP, Sun WS, Zhao Q, Shi RH, Tian ZB, Li YQ, Li W, Zhi FC. Risk factors for ERCP-related complications: a prospective multicenter study. *Am J Gastroenterol* 2009; **104**: 31-40 [PMID: 19098846 DOI: 10.1038/ajg.2008.5]

8 **Donnellan F**, Byrne MF. Prevention of Post-ERCP Pancreatitis. *Gastroenterol Res Pract* 2012; **2012**: 796751 [PMID: 21845187 DOI: 10.1155/2012/796751]

9 **Williams EJ,** Taylor S, Fairclough P. Risk factors for complication following CPRE; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39: 793-801 [DOI: 10.1055/s-2007-966723]

10 **Chen JJ**, Wang XM, Liu XQ, Li W, Dong M, Suo ZW, Ding P, Li Y. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. *Eur J Med Res* 2014; **19**: 26 [PMID: 24886445 DOI: 10.1186/2047-783X-19-26]

11 **Dumonceau JM**, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, Marek T, Baron TH, Hassan C, Testoni PA, Kapral C; European Society of Gastrointestinal Endoscopy. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. *Endoscopy* 2014; **46**: 799-815 [PMID: 25148137 DOI: 10.1055/s-0034-1377875]

12 **ASGE Standards of Practice Committee.**, Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, Bruining DH, Eloubeidi MA, Fanelli RD, Faulx AL, Gurudu SR, Kothari S, Lightdale JR, Qumseya BJ, Shaukat A, Wang A, Wani SB, Yang J, DeWitt JM. Adverse events associated with ERCP. *Gastrointest Endosc* 2017; **85**: 32-47 [PMID: 27546389 DOI: 10.1016/j.gie.2016.06.051]

13 **Tenner S**, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol* 2013; **108**: 1400-15; 1416 [PMID: 23896955 DOI: 10.1038/ajg.2013.218]

14 **Leerhøy B**, Nordholm-Carstensen A, Novovic S, Hansen MB, Jørgensen LN. Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: results from a Danish cohort study. *Pancreas* 2014; **43**: 1286-1290 [PMID: 25003219 DOI: 10.1097/MPA.0000000000000169]

15 **Wong LL**, Tsai HH. Prevention of post-ERCP pancreatitis. *World J Gastrointest Pathophysiol* 2014; **5**: 1-10 [PMID: 24891970 DOI: 10.4291/wjgp.v5.i1.1]

16 **Ding X**, Chen M, Huang S, Zhang S, Zou X. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. *Gastrointest Endosc* 2012; **76**: 1152-1159 [PMID: 23164513 DOI: 10.1016/j.gie.2012.08.021]

17 **Yaghoobi M**, Rolland S, Waschke KA, McNabb-Baltar J, Martel M, Bijarchi R, Szego P, Barkun AN. Meta-analysis: rectal indomethacin for the prevention of post-ERCP pancreatitis. *Aliment Pharmacol Ther* 2013; **38**: 995-1001 [PMID: 24099466 DOI: 10.1111/apt.12488]

18 **Sun HL**, Han B, Zhai HP, Cheng XH, Ma K. Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. *Surgeon* 2014; **12**: 141-147 [PMID: 24332479 DOI: 10.1016/j.surge.2013.10.010]

19 **Murray B**, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. *Gastroenterology* 2003; **124**: 1786-1791 [PMID: 12806612 DOI: 10.1016/S0016-5085(03)00384-6]

20 **Sotoudehmanesh R**, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. *Am J Gastroenterol* 2007; **102**: 978-983 [PMID: 17355281 DOI: 10.1111/j.1572-0241.2007.01165.x]

21 **Rainio M**, Lindström O, Udd M, Louhimo J, Kylänpää L. Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units. *J Gastrointest Surg* 2017; **21**: 1270-1277 [PMID: 28374181 DOI: 10.1007/s11605-017-3412-3]

22 **Levenick JM**, Gordon SR, Fadden LL, Levy LC, Rockacy MJ, Hyder SM, Lacy BE, Bensen SP, Parr DD, Gardner TB. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. *Gastroenterology* 2016; **150**: 911-7; quiz e19 [PMID: 26775631 DOI: 10.1053/j.gastro.2015.12.040]

23 **Gooshe M**, Abdolghaffari AH, Nikfar S, Mahdaviani P, Abdollahi M. Antioxidant therapy in acute, chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis: An updated systematic review and meta-analysis. *World J Gastroenterol* 2015; **21**: 9189-9208 [PMID: 26290647 DOI: 10.3748/wjg.v21.i30.9189]

24 **Fuentes-Orozco C**, Dávalos-Cobián C, García-Correa J, Ambriz-González G, Macías-Amezcua MD, García-Rentería J, Rendón-Félix J, Chávez-Tostado M, Cuesta-Márquez LA, Alvarez-Villaseñor AS, Cortés-Flores AO, González-Ojeda A. Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest? *World J Gastroenterol* 2015; **21**: 6745-6753 [PMID: 26074713 DOI: 10.3748/wjg.v21.i21.6745]

25 **Katsinelos P**, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. *Gastrointest Endosc* 2005; **62**: 105-111 [PMID: 15990827 DOI: 10.1016/S0016-5107(05)01574-9]

26 **Cotton PB**, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointest Endosc* 1991; **37**: 383-393 [PMID: 2070995 DOI: 10.1016/S0016-5107(91)70740-2]

27 **Cooper ST**, Slivka A. Incidence, risk factors, and prevention of post-ERCP pancreatitis. *Gastroenterol Clin North Am* 2007; **36**: 259-276, vii-viii [PMID: 17533078 DOI: 10.1016/j.gtc.2007.03.006]

28 **Inamdar S**, Han D, Passi M, Sejpal DV, Trindade AJ. Rectal indomethacin is protective against post-ERCP pancreatitis in high-risk patients but not average-risk patients: A systematic review and meta-analysis. *Gastrointest Endosc* 2017; **85**: 67-75 [PMID: 27612923 DOI: 10.1016/j.gie.2016.08.034]

29 **Yang C**, Zhao Y, Li W, Zhu S, Yang H, Zhang Y, Liu X, Peng N, Fan P, Jin X. Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of post-ERCP pancreatitis: An updated meta-analysis of randomized controlled trials. *Pancreatology* 2017; **17**: 681-688 [PMID: 28734720 DOI: 10.1016/j.pan.2017.07.008]

30 **Kochar B**, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, Khashab MA, Kalloo AN, Singh VK. Incidence, severity, and mortality of post-ERCP pancreatitis: A systematic review by using randomized, controlled trials. *Gastrointest Endosc* 2015; **81**: 143-149.e9 [PMID: 25088919 DOI: 10.1016/j.gie.2014.06.045]

31 **Mazen Jamal M**, Yoon EJ, Saadi A, Sy TY, Hashemzadeh M. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. *Am J Gastroenterol* 2007; **102**: 966-975 [PMID: 17319932 DOI: 10.1111/j.1572-0241.2007.01127.x]

32 **Moffatt DC**, Yu BN, Yie W, Bernstein CN. Trends in utilization of diagnostic and therapeutic ERCP and cholecystectomy over the past 25 years: a population-based study. *Gastrointest Endosc* 2014; **79**: 615-622 [PMID: 24119510 DOI: 10.1016/j.gie.2013.08.028]

33 **Tse F**, Yuan Y, Moayyedi P, Leontiadis GI. Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. *Endoscopy* 2013; **45**: 605-618 [PMID: 23807804 DOI: 10.1055/s-0032-1326640]

34 **Mazaki T**, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. *J Gastroenterol* 2014; **49**: 343-355 [PMID: 23612857 DOI: 10.1007/s00535-013-0806-1]

35 **Choudhary A**, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, Roy PK. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: A meta-analysis and systematic review. *Gastrointest Endosc* 2011; **73**: 275-282 [PMID: 21295641 DOI: 10.1016/j.gie.2010.10.039]

36 **Elmunzer BJ**, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. *N Engl J Med* 2012; **366**: 1414-1422 [PMID: 22494121 DOI: 10.1056/NEJMoa1111103]

37 **Sethi S**, Sethi N, Wadhwa V, Garud S, Brown A. A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. *Pancreas* 2014; **43**: 190-197 [PMID: 24518496 DOI: 10.1097/MPA.0000000000000090]

38 **Puig I**, Calvet X, Baylina M, Isava Á, Sort P, Llaó J, Porta F, Vida F. How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis. *PLoS One* 2014; **9**: e92922 [PMID: 24675922 DOI: 10.1371/journal.pone.0092922]

39 **Luo H**, Zhao L, Leung J, Zhang R, Liu Z, Wang X, Wang B, Nie Z, Lei T, Li X, Zhou W, Zhang L, Wang Q, Li M, Zhou Y, Liu Q, Sun H, Wang Z, Liang S, Guo X, Tao Q, Wu K, Pan Y, Guo X, Fan D. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial. *Lancet* 2016; **387**: 2293-2301 [PMID: 27133971 DOI: 10.1016/S0140-6736(16)30310-5]

40 **Kubiliun NM**, Adams MA, Akshintala VS, Conte ML, Cote GA, Cotton PB, Dumonceau JM, Elta GH, Fogel EL, Freeman ML, Lehman GA, Naveed M, Romagnuolo J, Scheiman JM, Sherman S, Singh VK, Elmunzer BJ; United States Cooperative for Outcomes Research in Endoscopy (USCORE). Evaluation of Pharmacologic Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Systematic Review. *Clin Gastroenterol Hepatol* 2015; **13**: 1231-9; quiz e70-1 [PMID: 25579870 DOI: 10.1016/j.cgh.2014.11.038]

41 **Akshintala VS**, Hutfless SM, Colantuoni E, Kim KJ, Khashab MA, Li T, Elmunzer BJ, Puhan MA, Sinha A, Kamal A, Lennon AM, Okolo PI, Palakurthy MK, Kalloo AN, Singh VK. Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis. *Aliment Pharmacol Ther* 2013; **38**: 1325-1337 [PMID: 24138390 DOI: 10.1111/apt.12534]

42 **He X**, Zheng W, Ding Y, Tang X, Si J, Sun LM. Rectal Indomethacin Is Protective against Pancreatitis after Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-Analysis. *Gastroenterol Res Pract* 2018; **2018**: 9784841 [PMID: 29861721 DOI: 10.1155/2018/9784841]

**P-Reviewer:** Chiu KW, Contini S, Jadallah KA **S-Editor:** Yan JP

**L-Editor: E-Editor:**

**Specialty type:** Medicine, research and experimental
**Country of origin:** Romania
**Peer-review report classification**
**Grade A (Excellent):** 0
**Grade B (Very good):** 0
**Grade C (Good):** C, C
**Grade D (Fair):** D **Grade E (Poor):** 0

**Figure 1 Percentages of patients with acute pancreatitis in the three groups.** PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.

**Figure 2 CRP evolution from baseline, at 6 h and at 24 h, compared in the three study arms.** CRP: C-reactive protein.

**Table 1 Baseline characteristics of patients in** **the control group and the study groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Control group****(*n* = 98)** | **Study group A****(*n* = 32)** | **Study group B****(*n* = 56)** | ***P*** |
| Female | 44 | 14 | 40 | 0.059 |
| Male | 54 | 18 | 16 | 0.086 |
| Age, yr | 64.47 | 63.56 | 64.50 | 0.976 |
| Comorbid conditions | 68 | 24 | 40 | 0.910 |
| * Diabetes mellitus type 2
 | 4 | 0 | 4 | 0.529 |
| * Hypertension
 | 24 | 10 | 6 | 0.591 |
| * Ischemic heart disease
 | 8 | 6 | 6 | 0.399 |
| * Dyslipidemia
 | 8 | 7 | 7 | 0.247 |
| * Hypothyroidism
 | 0 | 0 | 4 | 0.093 |
| * Hepatic cirrhosis
 | 4 | 0 | 4 | 0.529 |
| Normal bilirubin pre-ERCP | 20 | 16 | 14 | 0.066 |
| Previous cholecystectomy | 40 | 10 | 24 | 0.734 |
| Dilated bile duct pre-ERCP  | 4 | 0 | 4 | 0.529 |

ERCP: Endoscopic retrograde cholangiopancreatography.

**Table 2 Pearson’s chi-squared test to compare risk factors’ occurrence in the three study arms**

|  |  |  |  |
| --- | --- | --- | --- |
| **PEP** | **Pearson’s chi-square** | ***df*** | ***P*** |
| Existent risk factors | 0.627 | 2 | 0.731, NS |
| Female sex | 5.651 | 2 | 0.059, NS |
| Young age | 3.030 | 2 | 0.220, NS |
| Normal bilirubin | 5.446 | 2 | 0.066, NS |
| Excess contrast agent | 2.409 | 2 | 0.300, NS |
| No. of cannulations | 0.645 | 2 | 0.724, NS |
| PEP | 1.835 | 2 | 0.399, NS |

NS: Non-significant; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.

**Table 3 Pearson’s chi-squared test comparison between the three study arms’ clinical and laboratory factors at 6 h**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Control arm** | **Arm 1**1 | **Arm 2**2 | **Chi-square** | ***P*** |
| Amylasemia at 6 h |  |  |  | 4.288 | 0.368 |
| < 3 × ULN | 81.6% | 100.0% | 85.7% |  |  |
| > 3 × ULN | 18.4% | 0.0% | 14.3% |  |  |
| Lipasemia at 6 h |  |  |  | 10.046 | 0.040 |
| < 3 × ULN | 69.4% | 68.7% | 71.4% |  |  |
| > 3 × ULN | 30.6% | 31.3% | 28.6% |  |  |
| CRP at 6 hr |  |  |  | 12.165 | 0.058 |
| Normal | 49.0% | 56.2% | 57.1% |  |  |
| Mild increase | 20.4% | 12.5% | 35.7% |  |  |
| Moderate increase | 26.5% | 31.2% | 0.0% |  |  |
| Severe increase | 4.1% | 0.0% | 7.1% |  |  |
| Clinico-biologic status at 6 h |  |  |  | 0.397 | 0.820 |
| PEP absent | 91.8% | 87.5% | 92.9% |  |  |
| PEP | 8.2% | 12.5% | 7.1% |  |  |

1Study group A treatment regimen; 2Study group B treatment regimen; CRP: C-reactive peptide; ULN: Upper limit of normal; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.

**Table 4 Pearson’s chi-squared test comparison between the three study arms’ clinical and laboratory factors at 24 h**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Control arm** | **Arm 1**1 | **Arm 2**2 | **Chi-square** | ***P*** |
| Amylasemia at 24 h |  |  |  | 11.835 | 0.019 |
| < 3 × ULN | 91.8% | 100.0% | 71.4% |  |  |
| > 3 × ULN | 8.2% | 0.0% | 28.6% |  |  |
| Lipasemia at 24 h |  |  |  | 9.889 | 0.029 |
| < 3 × ULN | 91.8% | 87.5% | 71.4% |  |  |
| > 3 × ULN | 8.2% | 12.5% | 28.6% |  |  |
| CRP at 24 h |  |  |  | 12.824 | 0.046 |
| Normal | 49.0% | 43.8% | 64.3% |  |  |
| Mild increase | 20.4% | 0.0% | 7.1% |  |  |
| Moderate increase | 22.4% | 56.2% | 21.4% |  |  |
| Severe increase | 8.2% | 0.0% | 7.1% |  |  |
| Clinico-biologic status at 24 h |  |  |  | 2.793 | 0.247 |
| PEP absent | 91.8% | 87.5% | 78.6% |  |  |
| PEP | 8.2% | 12.5% | 21.4% |  |  |

1Study group A treatment regimen; 2Study group B treatment regimen; CRP: C-reactive peptide; ULN: Upper limit of normal; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.